Yendou secures 1.3 million US dollars in pre-seed financing

The startup successfully closes a pre-seed financing round, led by b2venture and supported by industry investors. The aim is to develop a clinical operations automation platform for the pharmaceutical industry.

Berlin - Yendou has successfully closed a pre-seed financing round of 1.3 million US dollars. The funding will be used to advance the development of the first clinical operations automation platform for the pharmaceutical industry. The financing round was led by venture capital firm b2venture, supported by Heartfelt, Infinita Fund and various angel investors from the pharmaceutical industry. Among them is Meri Beckwith, co-founder of new CRO challenger Lindus Health.

Rapid acceptance in the global clinician community

Since its launch in March 2023, Yendou has seen rapid adoption with over 1,200 clinicians from 46 countries. This positive response led Yendou to open its platform to pharmaceutical companies in a closed beta offering.

Yendou's automation platform aims to accelerate the operational efficiency of clinical trials and shorten the development time of new drugs in oncology. It aims to reduce research and development costs by connecting, selecting and integrating clinical trial sites for Phase II and Phase III trials.

Importance of the platform in the context of clinical trials

The funds provided will be used to expand the offering in the automated selection of clinical trial sites and to meet the high demand that Yendou has generated since its launch less than a year ago.

Yendou addresses the often overlooked problem of clinic recruitment in cancer clinical trials, which is a factor in the success of patient recruitment. The platform enables pharmaceutical companies to efficiently select the best clinics for their trials.

Background of the founders and team competencies

Zina Sarif, CEO and co-founder of Yendou, brings deep experience as a clinical researcher in oncology, while her co-founder Patrick Rogg worked as a software engineer at Amazon Web Services and Citadel. The team combines a deep understanding of the industry with technical expertise.

Recognition from investors

Investors, including Johanna Junkermann from b2venture, emphasize Yendou's ability to generate immediate market interest. CEO Zina Sarif's deep industry knowledge and network position the company as unique in creating a game-changing product for the pharma and biotech industry.